CD2BP2 Polyclonal Antibody BT-AP01450
Specifications
| 20ul / 50ul / 100ul |
Background:
CD2BP2 encodes a bi-functional protein (CD2 cytoplasmic tail binding protein 2). In the cytoplasm, the encoded protein binds the cytoplasmic tail of human surface antigen CD2 via its C-terminal GYF domain, and regulate CD2-triggered T lymphocyte activation. In the nucleus, this protein is a component of the U5 small nuclear ribonucleoprotein complex and is involved in RNA splicing. A pseudogene has been identified on chromosome 7. Alternative splicing results in multiple transcript variants but their biological validity has not been determined.
Classification:
Primary antibody
Alternative names:
CD2BP2; KIAA1178; CD2 antigen cytoplasmic tail-binding protein 2; CD2 cytoplasmic domain-binding protein 2; CD2 tail-binding protein 2
Species reactivity:
Human;Monkey
Host:
Rabbit
Isotype:
IgG
Immunogen:
The antiserum was produced against synthesized peptide derived from human CD2 Tail-binding. AA range:101-150
Concentration:
1 mg/ml
Molecular weight:
37646
Applications:
WB, IHC-p, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.